Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 22, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new method to help with surgery for women who have benign ovarian cysts caused by endometriosis. Specifically, it compares the use of a special hemostatic agent, which helps stop bleeding, to traditional suturing (stitching) during laparoscopic surgery (a minimally invasive type of surgery) to see which method better preserves ovarian function and ensures safety. Researchers want to know if using this hemostatic agent can improve outcomes for women undergoing this procedure.

To participate in this trial, women aged 19 to 45 who have regular menstrual cycles and have been diagnosed with endometriosis via ultrasound may be eligible. However, those who are pregnant, breastfeeding, or have certain other health issues would not qualify. If you join the study, you can expect to have the same laparoscopic ovarian cystectomy but with the possibility of either treatment method—either the hemostatic agent or suturing. Your participation will help researchers understand which method is safer and more effective for preserving ovarian health after surgery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Informed consent.
• • Age: 19-45 year-old women
• • American Society of Anesthesiologists Physical Status classification 1 or 2
• • Plan of laparoscopic ovarian cystectomy for unilateral or bilateral ovarian endometriosis diagnosed by ultrasonography
• • Regular menstruation every 21-45 days
• Exclusion Criteria:
• • No 'ovarian' endometriosis
• • Suspicious disease of ovarian malignancy
• • Age: 18 and younger, 46 and older
• • Pregnancy or breastfeeding.
• • Lower than 0.05 ng/ml of serum Anti-mullerian hormone level
• • Hormonal therapy within recent 3 months
• • Considered as inappropriate by the researcher's judgment.